SCHEMBL25363642

SCHEMBL25363642

C=CCC1(CC=C)CC(C(=O)O)N(C(=O)O)C1=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22636071 1.00 ACE (0.31) ACE
SCHEMBL8295119 0.81 ACE (0.31) ACE
SCHEMBL12741725 0.81 ACE (0.31) ACE
SCHEMBL28777416 0.81 KLK7 (0.31)
SCHEMBL18241829 0.79
SCHEMBL8294058 0.71 TP53 (0.33) ACE
SCHEMBL25191423 0.71 ACE (0.36) ACE
SCHEMBL25191422 0.71 ACE (0.36) ACE
SCHEMBL10138505 0.70 MAPK1 (0.32)
SCHEMBL12604934 0.70 MAPK1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed